Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents

2011 ◽  
Vol 83 (4) ◽  
pp. 602-607 ◽  
Author(s):  
Pin-Nan Cheng ◽  
Wen-Chun Liu ◽  
Hung-Wen Tsai ◽  
I-Chin Wu ◽  
Ting-Tsung Chang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Liver Histology

scholarly journals Correction to: A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Shanshan Chen ◽  
Haijun Huang ◽  
Wei Huang
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Chronic Hepatitis B ◽  
Alanine Aminotransferase ◽  
Liver Histology ◽  
Therapy Decision ◽  
Upper Limit

An amendment to this paper has been published and can be accessed via the original article.

Effect of newer oral antiviral agents on future therapy of chronic hepatitis B

2010 ◽  
Vol 15 (5) ◽  
pp. 801
Author(s):  
Robert P Perrillo ◽  
Patrick Marcellin
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Future Therapy

scholarly journals The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy

Viruses ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 934 ◽  
Author(s):  
Samuel Hall ◽  
Jessica Howell ◽  
Kumar Visvanathan ◽  
Alexander Thompson
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Standard Of Care ◽  
Current Standard ◽  
Hbsag Loss ◽  
Personalised Treatment ◽  
Treat All

Over 257 million individuals worldwide are chronically infected with the Hepatitis B Virus (HBV). Nucleos(t)ide analogues (NAs) are the first-line treatment option for most patients. Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are both potent, safe antiviral agents, have a high barrier to resistance, and are now off patent. They effectively suppress HBV replication to reduce the risk of cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Treatment is continued long-term in most patients, as NA therapy rarely induces HBsAg loss or functional cure. Two diverging paradigms in the treatment of chronic hepatitis B have recently emerged. First, the public health focussed “treat-all” strategy, advocating for early and lifelong antiviral therapy to minimise the risk of HCC as well as the risk of HBV transmission. In LMICs, this strategy may be cost saving compared to monitoring off treatment. Second, the concept of “stopping” NA therapy in patients with HBeAg-negative disease after long-term viral suppression, a personalised treatment strategy aiming for long-term immune control and even HBsAg loss off treatment. In this manuscript, we will briefly review the current standard of care approach to the management of hepatitis B, before discussing emerging evidence to support both the “treat-all” strategy, as well as the “stop” strategy, and how they may both have a role in the management of patients with chronic hepatitis B.

Lamivudine improves liver histology in chronic hepatitis B

1998 ◽  
Vol &NA; (1146) ◽  
pp. 9
Author(s):  
&NA;
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Liver Histology

Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine

2006 ◽  
Vol 26 (4) ◽  
pp. 399-405 ◽  
Author(s):  
Monika van Zonneveld ◽  
Pieter E Zondervan ◽  
Yilmaz Cakaloglu ◽  
Christopher Simon ◽  
Ulus S Akarca ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Additional Benefit ◽  
Liver Histology ◽  
Positive Chronic Hepatitis

1153 The impact of interferon-alfa (IFNA) therapy on liver histology in patients with HBEAG-negative chronic hepatitis B [HBEAG(-)CHB]

Hepatology ◽  
2003 ◽  
Vol 38 ◽  
pp. 712-712
Author(s):  
G PAPATHEODORIDIS ◽  
E CHOLONGITAS ◽  
E KANTA ◽  
K PETRAKI ◽  
I KETIKOGLOU ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Interferon Alfa ◽  
Liver Histology ◽  
Ifna Therapy ◽  
The Impact ◽  
Negative Chronic Hepatitis

scholarly journals Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy

2005 ◽  
Vol 21 (7) ◽  
pp. 841-849 ◽  
Author(s):  
M.-F. Yuen ◽  
D. H.-F. Chow ◽  
K. Tsui ◽  
B. C.-Y. Wong ◽  
J. C.-H. Yuen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Liver Histology ◽  
Lamivudine Therapy ◽  
Asian Patients
Sign in / Sign up

Export Citation Format

Share Document